Cargando…

Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells

Voltage-gated potassium channels are integral membrane proteins selectively permeable for potassium ions and activated upon change of membrane potential. Voltage-gated potassium channels of the Kv1.3 type were discovered both in plasma membrane and in inner mitochondrial membrane (mito Kv1.3 channel...

Descripción completa

Detalles Bibliográficos
Autores principales: Teisseyre, Andrzej, Uryga, Anna, Michalak, Krystyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789826/
https://www.ncbi.nlm.nih.gov/pubmed/33437096
http://dx.doi.org/10.1016/j.molstruc.2021.129905
_version_ 1783633325307461632
author Teisseyre, Andrzej
Uryga, Anna
Michalak, Krystyna
author_facet Teisseyre, Andrzej
Uryga, Anna
Michalak, Krystyna
author_sort Teisseyre, Andrzej
collection PubMed
description Voltage-gated potassium channels are integral membrane proteins selectively permeable for potassium ions and activated upon change of membrane potential. Voltage-gated potassium channels of the Kv1.3 type were discovered both in plasma membrane and in inner mitochondrial membrane (mito Kv1.3 channels). For some time Kv1.3 channels located both in plasma membrane and in mitochondria are considered as a potentially new molecular target in several pathologies including some cancer disorders. Lipophilic nontoxic organic inhibitors of Kv1.3 channels may potentially find a clinical application to support therapy of some cancer diseases such as breast, pancreas and lung cancer, melanoma or chronic lymphocytic leukaemia (B-CLL). Inhibition of T lymphocyte Kv1.3 channels may be also important in treatment of chronic and acute respiratory diseases including severe pulmonary complication in corona virus disease Covid 19, however further studies are needed to confirm this supposition. Statins are small-molecule organic compounds, which are lipophilic and are widely used in treatment of hypercholesterolemia and atherosclerosis. Electrophysiological studies performed in our laboratory showed that statins: pravastatin, mevastatin and simvastatin are effective inhibitors of Kv1.3 channels in cancer cells of human T cell line Jurkat. We showed that application of the statins in the concentration range from 1.5 μM to 50 μM inhibited the channels in a concentration-dependent manner. The inhibitory effect was the most potent in case of simvastatin and the least potent in case of pravastatin. The inhibition was partially irreversible in case of simvastatin and fully reversible in case of pravastatin and mevastatin. It was accompanied by a significant acceleration of the current inactivation rate without any significant change of the activation rate. Mechanism of the inhibition is probably complex, including a direct interaction with the channel protein and perturbation of lipid bilayer structure, leading to stabilization of the inactivated state of the channels.
format Online
Article
Text
id pubmed-7789826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-77898262021-01-08 Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells Teisseyre, Andrzej Uryga, Anna Michalak, Krystyna J Mol Struct Article Voltage-gated potassium channels are integral membrane proteins selectively permeable for potassium ions and activated upon change of membrane potential. Voltage-gated potassium channels of the Kv1.3 type were discovered both in plasma membrane and in inner mitochondrial membrane (mito Kv1.3 channels). For some time Kv1.3 channels located both in plasma membrane and in mitochondria are considered as a potentially new molecular target in several pathologies including some cancer disorders. Lipophilic nontoxic organic inhibitors of Kv1.3 channels may potentially find a clinical application to support therapy of some cancer diseases such as breast, pancreas and lung cancer, melanoma or chronic lymphocytic leukaemia (B-CLL). Inhibition of T lymphocyte Kv1.3 channels may be also important in treatment of chronic and acute respiratory diseases including severe pulmonary complication in corona virus disease Covid 19, however further studies are needed to confirm this supposition. Statins are small-molecule organic compounds, which are lipophilic and are widely used in treatment of hypercholesterolemia and atherosclerosis. Electrophysiological studies performed in our laboratory showed that statins: pravastatin, mevastatin and simvastatin are effective inhibitors of Kv1.3 channels in cancer cells of human T cell line Jurkat. We showed that application of the statins in the concentration range from 1.5 μM to 50 μM inhibited the channels in a concentration-dependent manner. The inhibitory effect was the most potent in case of simvastatin and the least potent in case of pravastatin. The inhibition was partially irreversible in case of simvastatin and fully reversible in case of pravastatin and mevastatin. It was accompanied by a significant acceleration of the current inactivation rate without any significant change of the activation rate. Mechanism of the inhibition is probably complex, including a direct interaction with the channel protein and perturbation of lipid bilayer structure, leading to stabilization of the inactivated state of the channels. Elsevier B.V. 2021-04-15 2021-01-07 /pmc/articles/PMC7789826/ /pubmed/33437096 http://dx.doi.org/10.1016/j.molstruc.2021.129905 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Teisseyre, Andrzej
Uryga, Anna
Michalak, Krystyna
Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title_full Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title_fullStr Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title_full_unstemmed Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title_short Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells
title_sort statins as inhibitors of voltage-gated potassium channels kv1.3 in cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789826/
https://www.ncbi.nlm.nih.gov/pubmed/33437096
http://dx.doi.org/10.1016/j.molstruc.2021.129905
work_keys_str_mv AT teisseyreandrzej statinsasinhibitorsofvoltagegatedpotassiumchannelskv13incancercells
AT urygaanna statinsasinhibitorsofvoltagegatedpotassiumchannelskv13incancercells
AT michalakkrystyna statinsasinhibitorsofvoltagegatedpotassiumchannelskv13incancercells